Allurion Technologies

ALUR

Market cap $16.8M

Overview Fund Activity

2.16 USD

-0.03

1.37%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

2.18

+0.02

0.93%

1 day

-1.37%

5 days

-6.09%

1 month

-16.28%

3 months

-15.62%

6 months

-14.96%

Year to date

-79.29%

1 year

-86.29%

5 years

-98.81%

10 years

-98.81%

About: Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Employees: 137

Healthcare Medical Devices

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

54% more capital invested

Capital invested by funds: $4.44M [Q1] → $6.84M (+$2.4M) [Q2]

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

14.35% more ownership

Funds ownership: 23.39% [Q1] → 37.75% (+14.35%) [Q2]

13% less funds holding

Funds holding: 24 [Q1] → 21 (-3) [Q2]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

See Fund Rankings

Financial journalist opinion

Zacks Investment Research

Allurion Technologies, Inc. (ALUR) Reports Q2 Loss, Misses Revenue Estimates

Allurion Technologies, Inc. (ALUR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.25 per share a year ago.

Allurion Technologies, Inc. (ALUR) Reports Q2 Loss, Misses Revenue Estimates

Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript

Allurion Technologies Inc. (NYSE:ALUR ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Shantanu K. Gaur - Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director Tara Brady - Corporate Participant Conference Call Participants Joshua Thomas Jennings - TD Cowen, Research Division Keay Thomas Nakae - Chardan Capital Markets, LLC, Research Division Michael Toomey - Jefferies LLC, Research Division Operator Hello, and thank you for standing by.

Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript

Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook Announced new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry Signed term sheet with strategic partner to enhance manufacturing and distribution capabilities and R&D pipeline,.

Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960.

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a new strategic direction with an increasing focus on low-dose GLP-1 combination therapy, muscle mass maintenance, and US market entry. The company has reported on real-world data from nearly 20,000 patients that demonstrate that patients using the Allurion Program lose weight immediately and through a focus on behavior change, keep the weight off while incre.

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced new publications on long-term weight loss results with the Allurion Program. In the first study, 522 patients treated with the Allurion Program across nine international obesity centers reduced their weight, on average, by 14.4kg (32lbs) or 13.9% of total body weight in just four months. One year later, the average weight loss was 13.9kg (31lbs) or 13.2% of t.

Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program

Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company specializing in bariatric and obesity care. This new partnership draws upon Minogue Medical's 40-year experience in the Canadian market and reflects Allurion's commitment to establishing a new standard of care in obesity management focused on metabolicall.

Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to the Food & Drug Administration (FDA) and additional, supportive analyses from the AUDACITY Study that meet both of the pre-specified co-primary endpoints. Topline results announced previously showed that the AUDACITY Study met its first co-primary endpoint related to.

Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting. This data include findings from a global, real-world experience evaluating body composition outcomes that demonstrate sustained weight loss, significant fat loss, and preservation of muscle mass with the Allurion Program and one of the longest real-wor.

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

Allurion to Present at Jefferies Global Healthcare Conference

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET. A webcast of the presentation will be available in the Events & Presentations section of Allurion's investor.

Allurion to Present at Jefferies Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™